Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116383

IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1,25 dihydroxyvitamin D3.

D L Lacey, L E Grosso, S A Moser, J Erdmann, H L Tan, R Pacifici, and D T Villareal

Department of Pathology, Jewish Hospital of St. Louis, Washington University, Missouri 63110.

Find articles by Lacey, D. in: PubMed | Google Scholar

Department of Pathology, Jewish Hospital of St. Louis, Washington University, Missouri 63110.

Find articles by Grosso, L. in: PubMed | Google Scholar

Department of Pathology, Jewish Hospital of St. Louis, Washington University, Missouri 63110.

Find articles by Moser, S. in: PubMed | Google Scholar

Department of Pathology, Jewish Hospital of St. Louis, Washington University, Missouri 63110.

Find articles by Erdmann, J. in: PubMed | Google Scholar

Department of Pathology, Jewish Hospital of St. Louis, Washington University, Missouri 63110.

Find articles by Tan, H. in: PubMed | Google Scholar

Department of Pathology, Jewish Hospital of St. Louis, Washington University, Missouri 63110.

Find articles by Pacifici, R. in: PubMed | Google Scholar

Department of Pathology, Jewish Hospital of St. Louis, Washington University, Missouri 63110.

Find articles by Villareal, D. in: PubMed | Google Scholar

Published April 1, 1993 - More info

Published in Volume 91, Issue 4 on April 1, 1993
J Clin Invest. 1993;91(4):1731–1742. https://doi.org/10.1172/JCI116383.
© 1993 The American Society for Clinical Investigation
Published April 1, 1993 - Version history
View PDF
Abstract

IL-1-induced osteoblast IL-6 production represents one possible mechanism by which IL-1 augments bone resorption. In this report, we show that the murine osteoblastic cell line (MC3T3-E1) expresses type 1 IL-1 receptors based on 125I-HrIL1 alpha binding, blocked by type 1 IL-1R antibodies (35F5), and analysis of MC3T3 RNA by reverse transcription (RT)-DNA amplification and Northern analysis. MC3T3 cells do not express detectable type 2 IL-1R mRNA by RT-DNA amplification. IL-1 induces (IL-1 ED50, 0.1 pM) IL-6 production through the type 1 IL-1R as 35F5 antibodies block IL-1-stimulated IL-6 production. Vitamin D3 increases IL-1R expression dose- and metabolite-dependently, with 1,25-(OH)2D3 having the greatest potency, and also enhances IL-1's capacity to stimulate IL-6 production at low IL-1 levels. Both IL-1 and 1,25-(OH)2D3 induce type 1 IL-1R and not type 2 IL-1R upregulation based on ligand binding and RT-DNA amplification. Increased IL-1R expression requires a 5-7-h treatment and is protein/RNA synthesis dependent. These observations imply that IL-1-induced IL-6 production in osteoblasts is mediated by type 1 IL-1Rs and that increased IL-1R expression could play a role in mediating IL-1-induced skeletal responses.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1731
page 1731
icon of scanned page 1732
page 1732
icon of scanned page 1733
page 1733
icon of scanned page 1734
page 1734
icon of scanned page 1735
page 1735
icon of scanned page 1736
page 1736
icon of scanned page 1737
page 1737
icon of scanned page 1738
page 1738
icon of scanned page 1739
page 1739
icon of scanned page 1740
page 1740
icon of scanned page 1741
page 1741
icon of scanned page 1742
page 1742
Version history
  • Version 1 (April 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts